Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease

Expert Review of Hematology

Volumn 6, Issue 4, 2013, Pages 475-483

  Malerba, Mario ^a   Clini, Enrico ^b   Malagola, Michele ^a   Avanzi, Gian Carlo ^c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c Amedeo Avogadro University   (Italy)

Author keywords

acute exacerbation; chronic obstructive pulmonary disease; inflammation; platelet activation

Indexed keywords

ATHEROSCLEROSIS; DISEASE PROGRESSION; HUMANS; PLATELET ACTIVATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84894156288     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2013.814835     Document Type: Review

References (80)

1. Vanfleteren LW, Spruit MA, Groenen M et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 187, 728-735 (2013).
2. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000).
3. Curkendall SM, DeLuise C, Jones JK et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann. Epidemiol. 16, 63-70 (2006).
4. MacNee W, Maclay J, Mcallister D. Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 5, 824-833 (2008).
5. Sin DD, Anthonisen NR, Soriano JB et al. Mortality in COPD: role of comorbidities. Eur. Respir. J. 28, 1245-1257 (2006).
6. McAllister DA, Maclay JD, Mills NL et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur. Respir. J. 39,1097-1103 (2012).
7. Donaldson GC, Hurst JR, Smith CJ et al. Increased risk of myocardical infarction and stroke following exacerbation of COPD. Chest 137(5), 1091-1097 (2010).
8. Hoffman M. Remodeling the blood coagulation cascade. J. Thromb. Thrombolysis, 16(1-2), 17-20 (2003).
9. Di Santo A, Amore C, Dell'Elba G et al. Glycogen synthase kinase-3 negatively regulates tissue factor expression in monocytes interacting with activated platelets. J. Thromb. Haemost. 9(5), 1029-1039 (2011).
10. Schumacher A, Liebers U, John M, et al. P-selectin glycoprotein ligand-1 (PSGL-1) is up-regulated on leucocytes from patients with chronic obstructive pulmonary disease. Clin. Exp. Immunol. 142(2), 370-376 (2005).
11. Davi G, Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482-2494 (2007).
12. Duvoix A, Dickens J, Haq I et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 68, 670-676 (2013).
13. Dahl M, Tybjaerg-Hansen A, Vestbo J et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164, 1008-1011 (2001).
14. Hurst JR, Vestbo J, Anzueto A et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 363, 1128-1138 (2010).
15. Stec JJ, Silbershatz H, Tofler GH et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 102, 1634-1638 (2000).
16. Lambert MP, Sachais BS, Kowalska MA. Chemokines and thrombogenicity. Thromb. Haemost. 97, 722-729 (2007).
17. Wedzicha JA, Syndercombe-Court, Tan KC. Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxaemia. Thorax 46, 504-507 (1991).
18. Patrono C, Patrignani P, Rocca B et al. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. Thromb. Haemost. 74, 396-400 (1995).
19. Rolin S, Masereel B, Dogne JM. Prostanoids as pharmacological targets in COPD and asthma. Eur. J. Pharmacol. 533, 89-100 (2006).
20. Davì G, Basili S, Vieri M et al. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group. Am. J. Respir. Crit. Care Med. 156, 1794-1799 (1997).
21. Ponicke K, Sternitzky R, Mest HJ. Stimulation of aggregation and thromboxane A2 formation of human platelets by hypoxia. Prostaglandins Leukot Med. 29, 49-59 (1987).
22. Patrono C. Thromboxane synthesis inhibitors and receptor antagonists. Thromb. Res. Suppl. 11, 15-23 (1990).
23. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J. Clin. Invest. 115, 3378-3384 (2005).
24. Boots AW, Haenen GR, Bast A. Oxidant metabolism in chronic obstructive pulmonary disease. Eur. Respir. J. Suppl. 46, 14s-27s (2003).
25. Nowak D, Kasielski M, Antczak A et al. Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. Respir. Med. 93, 389-396 (1999).
26. Nowak D, Kalucka S, Bialasiewicz P et al. Exhalation of H2O2 and thiobarbituric acid reactive substances (TBARs) by healthy subjects. Free Radic. Biol. Med. 30, 178-186 (2001).
27. Praticò D, Basili S, Vieri M et al. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am. J. Respir. Crit. Care Med. 158, 1709-1714 (1998).
28. Devaraj S, Hirany SV, Burk RF et al. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin. Chem. 47, 1974-1979 (2001).
29. Pernerstorfer T, Stohlawetz P, Stummvoll G et al. Low-dose aspirin does not lower in vivo platelet activation in healthy smokers. Br. J. Haematol. 102, 1229-1231 (1998).
30. Hioki Y, Aoki N, Kawano K et al. Acute effects of cigarette smoking on plateletdependent thrombin generation. Eur. Heart J. 22, 56-61 (2001).
31. Hung J, Lam JYT, Lacoste L et al. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation, 92, 2432-2436 (1995).
32. Harding SA, Sarma J, Josephs DH et al. Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation 109, 1926-1929 (2004).
33. Heeschen C, Dimmeler S, Hamm CW et al.; CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 348, 1104-1111 (2003).
34. André P, Nannizzi-Alaimo L, Prasad SK et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106, 896-899 (2002).
35. Falco A, Romano M, Iapichino L et al. Increased solubile CD40 ligand levels in cystic fibrosis. J. Thromb. Haemost. 2, 557-560 (2004).
36. Fimognari FL, Scarlata S, Conte ME et al. Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 3(1), 89-96 (2008).
37. Miller GJ, Bauer KA, Cooper JA et al. Activation of the coagulant pathway in cigarette smokers. Thromb. Haemost. 79, 549-553 (1998).
38. Dominick J. Angiolillo, Goto S. Basic principles of platelet biology and clinical implications. Circ. J. 74, 597-607 (2010).
39. da Costa Martins PA, van Gils JM, Mol A et al. Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins. J. Leukoc. Biol. 79, 499-507 (2006).
40. Schober A, Manka D, von Hundelshausen P et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 106, 1523-1529 (2002).
41. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil- interactions: linking hemostasis and inflammation. Blood Rev. 21, 99-111 (2007).
42. Alciato F, Sainaghi PP, Sola D et al. TNF-alpha, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes/macrophages. J. Leukoc. Biol. 87(5), 869 (2010).
43. Muñoz X, Sumoy L, Ramírez-Lorca R et al. Human vitamin K-dependent GAS6: gene structure, allelic variation, and association with stroke. Hum. Mutat. 23(5), 506-512 (2004).
44. Hurtado B, Abasolo N, Muñoz X et al. Association study between polymorphims in GAS6-TAM genes and carotid atherosclerosis. Thromb. Haemost. 104(3), 592-598 (2010).
45. van Eeden SF, Sin DD. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 75, 224-238 (2008).
46. Maclay JD, McAllister DA, Johnston S et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 66, 769-774 (2011).
47. De Castro J, Hernandez-Hernandez A, Rodriguez MC et al. Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma. Platelets 18, 43-51 (2007).
48. Ferroni P, Basili S, Martini F et al, Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease. J. Invest. Med. 48, 21-27 (2000).
49. Walter RE, Wilk JB, Larson MG et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 133, 19-25 (2008).
50. Sarma J, Laan CA, Alam S et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 105, 2166-2171 (2002).
51. Christie DJ, Kottke-Marchant K, Gorman RT. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Platelets 19, 104-110 (2008).
52. Gianetti J, Parri MS, Sbrana S et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb. Res. 118, 487-493 (2006).
53. Humbert M, Morrell N, Archer S et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, 13-24 (2004).
54. Maclay JD, McAllister DA, Mills NL et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 180, 513-520 (2009).
55. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J. Clin. Invest. 115, 3378-3384 (2005).
56. Borgel D, Clauser S, Bornstain C et al. Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Crit. Care Med. 34, 219-222 (2006).
57. Sainaghi PP, Alciato F, Carnieletto S et al. Gas evaluation in patients with acute dyspnea due to suspected pulmonary embolism. Respir. Med. 103(4), 589-594 (2009).
58. Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets 17, 577e85 (2006).
59. Smeeth L, Thomas SL, Hall AJ et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 351, 2611e18 (2004).
60. Crisafulli E, Marietta M, Venturelli E et al. Platelets count in chronic obstructive pulmonary disease [abstract]. Eur. Respir. J. 40(Suppl.), 76s (2012).
61. Ly HQ, Kirtane AJ, Murphy SA et al. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am. J. Cardiol. 98, 1-5 (2006).
62. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int. J. Clin. Pract. 63, 1509-1515 (2009).
63. Steiropoulos P, Papanas N, Nena E et al. Mean platelet volume and platelet distribution width in patients with chronic obstructive pulmonary disease: the role of comorbidities. Platelets 23, 447-454 (2012).
64. Cui H, Liu L, Wei Z et al. Clinical value of mean platelet volume for impaired cardiopulmonary function in very old male patients with chronic obstructive pulmonary disease. Arch. Gerontol. Geriatr. 54(2), 109-112 (2012).
65. Ulasli SS, Ozyurek BA, Yilmaz EB et al. Mean platelet volume as an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease. Pol. Arch. Med. Wewn. 122(6), 284-290 (2012).
66. Biljak VR, Pancirov D, Cepelak I et al. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets 22(6), 466-470 (2011).
67. Rutten FH, Cramer MJ, Lammers JW et al. Heart failure chronic obstructive pulmonary disease: an ignored combination? Eur. J. Heart Fail. 8, 706-711 (2006).
68. Klinkhardt U, Bauersachs R, Adams J et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin. Pharmacol. Ther. 73, 232-241 (2003).
69. Pettersen AÅ, Seljeflot I, Abdelnoor M et al. High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J. Am. Heart Assoc. 1(3), e000703 (2012).
70. Mora S, Wenger NK, Demicco DA et al. Determinants of residual risk in secondary prevention patients treated with high-versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation 125(16), 1979-1987 (2012).
71. Briasoulis A, Tousoulis D, Bakogiannis C et al. Novel anti-platelet agents for the treatment of stable angina pectoris. Curr. Pharm. Des. 19(9), 1581-1586 (2013).
72. Barrett NE, Holbrook L, Jones S et al. Future innovations in anti-platelet therapies. Br. J. Pharmacol. 154, 918-939 (2008).
73. Sin DD, Lacy P, York E et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 170, 760-765 (2004).
74. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60, 992-997 (2005).
75. Pedersen TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atheroscler. Suppl. 5(3), 81-87 (2004).
76. Macie C, Wooldrage K, Manfreda J et al. Inhaled corticosteroids and mortality in COPD. Chest 130, 640-646 (2006).
77. Calverley PM, Anderson JA, Celli B et al; TORCH investigators. Salmeterol and fl uticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775-789 (2007).
78. Eickelberg O, Roth M, Lorx R et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fi broblasts and vascular smooth muscle cells. J. Biol. Chem. 274, 1005-1010 (1999).
79. Afessa B, Morales IJ, Scanlon PD, Peters SG. Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive pulmonary disease admitted to an intensive care unit for acute respiratory failure. Crit. Care Med. 30, 1610-1615 (2002).
80. Lahousse L, Van der Bouwhuijsen QJA, Loth DV et al. Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly. The Rotterdam Study. Am. J. Respir. Crit. Care Med. 187, 58-64 (2013).